Overseas Innovative Drugs Roadshow – Seeking cooperation with Chinese innovative companies
- LMC5000747 Innovative asset with unique MoA inhibiting tumor cell migration and spread from EU seeking cooperation with China- LMP1464
- LMC5000458 Acute Myeloid Leukemia (AML) - NK Therapy
- LMC5001085 R&D Breakthrough of Orphan Drug for Dry Eye Syndrome
Event details
|
DATE Thursday, Oct 27, 2022 VENUE Online Webex / Zoom TIME 10:00 – 11:00 Berlin time (CET) 16:00 – 17:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by Oct 26, 2022 |
PRESENTERS Lingling Cao, CEO & Founder Guest speaker REGISTER +86 21 5386 3003 BD@lingmed.net |
Agenda
| CET 10:00 - 10:05 | Linkedbio services & projects introduction |
by Lingling (Chinese & English) |
| CET 10:05 - 10:20 | An innovative biotech roadshow: Innovative asset with unique MoA inhibiting tumor cell migration and spread from EU seeking cooperation with China- LMP1464 | by Guest speaker (English) |
| CET 10:20 - 10:35 | An innovative biotech roadshow: Acute Myeloid Leukemia (AML) - NK Therapy | by Guest speaker (English) |
| CET 10:35 - 10:50 | An innovative biotech roadshow: R&D Breakthrough of Orphan Drug for Dry Eye Syndrome | by Guest speaker (English) |
| CET 10:50 - 11:00 | Q&A | (English & Chinese) |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |